| Company/Division name | Arrowhead Pharmaceuticals, Inc. |
| Parent company | Arrowhead Pharmaceuticals, Inc. |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| What product(s) and/or service(s) were outsourced domestically? | Manufacturing |
| Year reshoring announced: | 2022 |
| Year reshoring implemented or to be implemented: | 2024 |
| Domestically, the work will be done: | In-house |
| City reshored to: | Verona |
| State(s) reshored to: | WI |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | pharmaceuticals |
| What domestic positive factors made reshoring more attractive? | Government Incentives, $2.5 M, refundable Wisconsin state income tax cred |
| Government Incentive dollar amount: | $16 million in tax increment |
